{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-035593","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.865432+00:00","generated_at":"2026-05-31T11:39:45.646575+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M","bullets":["Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).","Gross margin 60.2%; operating expenses down $0.7M YoY to $13.9M.","Net loss approximately breakeven, a $2.2M improvement vs Q2 2023 loss of $2.2M.","Adjusted EBITDA improved to $1.6M from $0.2M in prior year quarter.","FDA Orphan Drug and Rare Pediatric Disease Designation for nicotinamide riboside chloride in Ataxia Telangiectasia."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-035593","json":"https://secwatch.observer/filing/0001628280-24-035593.json","markdown":"https://secwatch.observer/filing/0001628280-24-035593.md","text":"https://secwatch.observer/filing/0001628280-24-035593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024035593/0001628280-24-035593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024035593/cdxc-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:39:45.646575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}